Hailemichael, Yared

The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

Varghese, S., Pramanik, S., Williams, L. J., Hodges, H. R., Hudgens, C. W., Fischer, G. M., Luo, C. K., Knighton, B., Tan, L., Lorenzi, P. L., et al. (2021) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 171

Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression

Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., et al. (2017) · Clinical Cancer Research

Angiogenesis and VEGF in CancerImmune cells in cancer

Cited by 97

Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.

Johnson, D. H., Hailemichael, Y., Foo, W. C., Hess, K. R., Haymaker, C. L., Wani, K. M., Lazar, A. J., Saberian, C. M., Bentebibel, S. E., Burton, E. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 9